-
Mashup Score: 1FDA Approves Label Updates to Include New Data for Axi-Cel in LBCL, Zanubrutinib in CLL - 11 month(s) ago
The FDA has approved label updates for zanubrutinib to include data from the ALPINE trial in relapsed/refractory chronic lymphocytic leukemia, and axicabtagene ciloleucel to include findings from the primary overall survival analysis of the ZUMA-7 trial in relapsed/refractory large B-cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Paper: Initial Results of a Phase 1 Dose Escalation Study of LP-168, a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton’s Tyrosine Kinase - 11 month(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 642. Chronic Lymp hocytic Leukemia: Clinical and Epidemiological: New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Hematology Disease Topics & Pathways: Non-Biological therapies, drug development, Therapies 1 The Ohio State University Comprehensive Cancer Center, Columbus, OH 2 Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 3 Duke Cancer Center, Durham, NC 4 Division of Hematology, The Ohio State University,
Source: ash.confex.comCategories: General Medicine News, Hematologists1Tweet-
LP-168 a next gen BTKi that binds covalently and non covalently to BTK, ORR of 66% in the higher dose ph1 and most CLL #lymsm #leusm with resistant mutations responding. https://t.co/RHSDHCKq64 https://t.co/zQ21UahWE1
-
.@us_fda Approves Label Updates to Include New Data for Axi-Cel in LBCL, Zanubrutinib in CLL #lymsm #leusm https://t.co/4YHqES6kjE